Abstract: This invention is for an improved method of treating the disease of hypoglycemia (low blood glucose), based on the discovery by the inventor of the etiology of the disease. The genesis of this invention is in the discovery that insulin alone does not control the uptake and regeneration of glucose by the liver. It has been discovered that hepatic storage of glucose following a meal requires the related function of insulin and serotonin. Hypoglycemia occurs during fasting and is due to an inappropriate release of serotonin to the liver. From this, the method of using a serotonin antagonist or an agent to block synthesis and/or storage of serotonin in timed relationship to ingested food to stop the action or the production of serotonin after glucose is no longer supplied to the portal vein is described. Then the liver can cease glucose uptake and begin production of glucose for the peripheral blood supply. The preferred antagonist is cyproheptadine.

Abstract: A biochemical membrane covered with sialic residues thereby provides a coating that masks the surface membrane from recognition and removal by the scavenging RES cells of the body.